New mechanism of action for class of chemotherapy drugs uncovered – 2
Narrator: This is NIH Health Matters, I’m Joe Balintfy. In recent years, some chemotherapy drugs called PARP inhibitors have been shown to be promising anticancer agents for breast and ovarian cancer. But new research is showing new details.
Pommier: So if you block the poly (ADP-ribose) polymerase, the PARP, then it’s much harder for the DNA to be repaired.
Narrator: Which ultimately causes cell death, says Dr. Yves Pommier at the NIH.
Pommier: In fact, what we found is that some of the drugs do more than that.
Narrator: These findings suggest that there may be two classes of PARP inhibitors. For more on this study and new cancer research, visit www.cancer.gov.Health Matters is produced by the National Institutes of Health, part of the U.S. Department of Health and Human Services.
About NIH Radio
NIH Radio offers free audio news programs from the National Institutes of Health, your reliable source for health information.
All NIH Radio content is in the public domain and can be used without charge or restriction provided that it is not used to misrepresent our agency nor used to suggest we endorse any private organization, product, or service.
NIH Radio is a service of the Office of Communications & Public Liaison.